The U.K. National Institute for Health and Care Excellence (NICE) has issued a brief stating that cancer treatment firm Sirtex Medical's SIR-Spheres Y-90 resin microspheres may be used by National Health Service (NHS) doctors to treat patients with inoperable primary liver cancer.
The microspheres are an alternative to standard therapy using transarterial chemoembolization, an interventional radiology procedure, or sorafenib, a kinase inhibitor drug.
The institute's briefing states that most patients treated with SIR-Spheres Y-90 resin microspheres require only a single treatment, compared with multiple procedures required by transarterial chemoembolization or daily doses of sorafenib, the company said.
